Perirenal Fat Thickness is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus
Jian Yang,Chuan Wang Li,Jing Ru Zhang,Honglin Qiu,Xiu Li Guo,Wei Wang
DOI: https://doi.org/10.2147/DMSO.S415477
2023-06-28
Abstract:Jian Yang, &ast Chuan Wang Li, &ast Jing Ru Zhang, Honglin Qiu, Xiu Li Guo, Wei Wang Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 364000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Wang; Xiu Li Guo, Department of Endocrinology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, 364000, People's Republic of China, Email ; Objective: Recent advances in perirenal adipose tissue (PAT) highlighted that PAT might involve in the pathogenesis of chronic inflammatory and dysfunctional metabolic diseases. This study assessed the association between perirenal fat thickness (PrFT) and metabolic dysfunction-associated fatty liver disease (MALFD) in type 2 diabetes mellitus (T2DM). Methods: This study comprised 867 eligible participants with T2DM. Trained reviewers collected anthropometric and biochemical measurements. The diagnosis of MAFLD was based on the latest international expert consensus statement. PrFT and fatty liver were evaluated by computed tomography. The visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by bioelectrical impedance analysis. The non-alcoholic fatty liver disease fibrosis score (NFS) and fibrosis-4 (FIB-4) index were used to assess progressive liver fibrosis in MAFLD. Results: Overall, the prevalence of MAFLD was 62.3% in T2DM. The PrFT in the MAFLD group was statistically increased than in the non-MAFLD group ( P < 0.05). Correlation analysis showed that PrFT was significantly correlated with dysfunctional metabolic factors like body mass index, waist circumference, triglycerides, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, uric acid, and insulin resistance. Multiple regression analysis revealed that PrFT was positively correlated with NFS ( β =0.146, P < 0.001) and FIB-4 ( β =0.082, P =0.025) in the MAFLD. In contrast, PrFT was negatively correlated with CT L-S ( β =− 0.188, P < 0.001). Furthermore, PrFT was also significantly associated with MAFLD independent of VFA and SFA, the OR (95% CI) was 1.279 (1.191– 1.374). Meanwhile, PrFT also had a good identifying value for MAFLD as VFA. The area under the curve (95% CI) value of PrFT identifying MAFLD was 0.782 (0.751– 0.812). The optimal cut-off value of PrFT was 12.6mm, with a sensitivity of 77.8% and specificity of 70.8%. Conclusion: PrFT was independently associated with MAFLD, NFS, and FIB-4 and showed a similar identifying value for MAFLD as VFA, which suggested that PrFT can be used as an alternative index to VFA. Keywords: metabolic dysfunction-associated fatty liver disease, liver fibrosis, perirenal fat thickness, obesity, type 2 diabetes mellitus Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease characterized by liver fat content exceeding 5% (hepatic steatosis), which in turn can progress to its severe forms like non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma. MAFLD was previously named non-alcoholic fatty liver disease (NAFLD). The golden criteria of NAFLD, NASH, and liver fibrosis were based on liver biopsy, which was not widely used in patients with NAFLD due to its invasive nature. Hence, the latest expert consensus statement set new "positive" criteria (hepatic steatosis in adults detected by imaging techniques, blood biomarkers, or liver histology). The novel classification downplays the importance of alcohol in the definition of NAFLD and highlights metabolic risk factors for NAFLD-related pathological progression. 1 Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia, rapidly increasing and becoming a major public concern worldwide. MAFLD and T2DM share the same metabolic risk factors like genetic factors, insulin resistance, dyslipidemia, obesity, and unhealthy lifestyle, 2 which cause a high prevalence of MAFLD in T2DM. The latest epidemiological data suggested that the prevalence of MAFLD was up to 55.2% in T2DM. 3 In addition to MAFLD-associated liver injury, it can worsen glycemic control and increase the incidence of diabetes-associated complications, such as cardiovascular disease, diabetic nephropathy, and diabetic retinopathy. 4 Current guidelines for the management of MAFLD in T2DM focused on developing effective strategies to treat metabolic risk factors, as well as preventing diabetes-related target organ damage and adverse liver outcomes. Obesity is a crucial risk factor that links MAFLD with T2DM. Obesity involves excessive adipose tissue accumulation i -Abstract Truncated-
endocrinology & metabolism